Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02102698 · ClinicalTrials.gov registry record · Phase 2
Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years
A Phase 2 study, sponsored by Emalex Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT02102698 is a Phase 2 study that has completed, run by Emalex Biosciences. The registered enrollment target is 40 participants.
The verdict
NCT02102698, a Phase 2 study, has completed, sponsored by Emalex Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
Tourette's Syndrome is a neurological disease characterized by motor and vocal tics. It has been hypothesized that abnormal interactions of dopamine with its receptors may cause the tics. The purpose of this study is to test the hypothesis that a drug (ecopipam) that selectively blocks dopamine D1/D5 receptors can reduce the frequency and severity of the tics.
Interventions
- DRUG Ecopipam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2014-06-19 |
| Est. Completion | 2019-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02102698
The ClinicalTrials.gov registry entry for NCT02102698 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emalex Biosciences, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ecopipam is the first listed.
NCT02102698 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02102698 about?
NCT02102698 is a clinical study titled "Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years". Tourette's Syndrome is a neurological disease characterized by motor and vocal tics. It has been hypothesized that abnormal interactions of dopamine with its receptors may cause the tics. The purpose of this study is to test the hypothesis that a drug (ecopipam) that selectively blocks dopamine D1/D...
What is the current status of trial NCT02102698?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2014-06-19. Estimated completion is 2019-12.
What interventions are being tested in trial NCT02102698?
The interventions under investigation include: Ecopipam (DRUG).
Who is sponsoring clinical trial NCT02102698?
This trial is sponsored by Emalex Biosciences, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.